Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
NCT06478602Phase 3Completed
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, open-label trial of allogeneic fecal microbiota in Liver cirrhosis (LC) (2 arms). Primary endpoints: Liver Stiffness by Transient Elastography (FibroScan) at 1 month and Implications of Fecal Microbiota Transplantation in Modulating Hepatic Encephalopathy at 1 month. Started Aug 2024; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06478602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478602.